We use cookies for a better user experience. Read our Privacy Policy
I Agree
Human Papillomavirus Vaccine Market
Human Papillomavirus Vaccine Market: Snapshot
Human papillomaviruses cause various types of cancers such as cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, oropharyngeal cancer, and genital warts. The human papillomavirus infection can be prevented by the vaccination against human papillomavirus. The human papillomavirus vaccine market was valued approximately US$ 2.0 Bn in 2016 and is anticipated to reach US$ 3.5 Bn by 2025, expanding at a CAGR of over 5.0% from 2017 to 2025. Approval of new human papillomavirus vaccines in various countries is likely to fuel the human papillomavirus vaccine market from 2017 to 2025.
Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection. CDC also states that about 14 million people are newly infected by human papillomavirus every year in the U.S. According to the Cancer Council Australia, almost all schools in Australia have chosen to participate in the National Human Papillomavirus Vaccination Program. More than 9 million doses of vaccine have been given to girls and young women in Australia. This initiation resulted in approximately 90% decrease in genital warts among heterosexual women and men under the age of 21 years and approximately 50% decrease in disease of high-grade cervical abnormalities in girls under 18 years of age.
High unmet needs are expected to create huge opportunities for existing players and new entrants in the global human papillomavirus vaccine market. These vaccines are used against various types of human papillomavirus, which provides ample opportunities for players operating in the global human papillomavirus vaccines market. Recent developments in research and development of human papillomavirus vaccines fuel the growth of the market during the forecast period. In December 2015, Merck & Co., Inc. announced that the U.S. FDA has approved an extended age indication for Gardasil 9, a nonavalent human papillomavirus vaccine to include use in males 16 to 26 years of age for the prevention of anal and penile cancers and genital warts caused by certain human papillomavirus types.
Human Papillomavirus Vaccine Market: Segmentation
The global human papillomavirus vaccine market has been categorized based on quadrivalent, and nonavalent and region. Quadrivalent, and nonavalent segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by bivalent segment. The launch of new and increasing incidences of cervical cancer are likely to propel the segment. In terms of indication type, cervical cancer dominated the segment in 2016 and it is anticipated to continue its dominance during the forecast period. Anal cancer was the second most leading segment in 2016 and it is likely to continue this trend from 2017 to 2025. Based on distribution channel, government entities held the largest share of the market. However, the segment is anticipated to lose market share during the forecast period owing to public and private alliances such as GAVI that are focused on vaccinating people in developing countries
Geographically, North America accounted for the largest share of global human papillomavirus vaccine market in 2016. Recent approvals received by key players of the market in the region are attributed for increase market share of the region. The market share of Asia Pacific is projected to increase during the forecast period. In July 2017, GlaxoSmithKline plc. Received approval for Cervarix from China FDA. This is anticipated to drive the human papillomavirus vaccine market in the region. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals is likely to boost the market in Latin America and Middle East & Africa.
Key players operating in the global human papillomavirus vaccine market include Merck & Co., Inc., GlaxoSmithKline plc. Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute of India Pvt. Ltd. These players adopted inorganic and organic growth strategies to increase their vaccine offerings, strengthen their reach across the globe, garner market share, and increase customer base.
The global human papillomavirus vaccine market has been segmented as below:
|
Valence |
|
|
Indication |
|
|
Distribution Channel |
|
|
Geography |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights
2. Assumptions and Acronyms Used
3. Research Approach & Methodology
3.1. Research Methodology Overview
3.2. Project Initiation
3.3. Secondary Research Methodology
3.4. Primary Research Methodology
3.5. Analysis Research Methodology
3.6. Final Report & Conclusions Research Methodology
4. Executive Summary: Global Human Papillomavirus Vaccine Market
5. Market Overview
5.1. Overview
5.2. Key Industry Events and Developments
5.3. Global Human Papillomavirus Vaccine Market Forecast and Analysis
5.4. Global Human Papillomavirus Vaccine Market Outlook
6. Market Dynamics
6.1. Drivers and Restraints Snapshot Analysis
6.2. Drivers
6.3. Restraints
6.4. Opportunity
6.5. Key Trends
6.6. Institutional Sales Overview, by Volume (No. of Unit Dose)
6.7. Pricing Analysis
6.8. Pipeline Analysis: Human Papillomavirus Vaccine
7. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Valence
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast by Valence, 2015–2025
7.3.1. Bivalent
7.3.2. Quadrivalent, and Nonavalent
7.4. Global Human Papillomavirus Vaccines Market Analysis, by Valence
7.5. Global Human Papillomavirus Vaccines Market Forecast, by Valence
7.6. Global Human Papillomavirus Vaccines Market Analysis, by Valence
8. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast by Indication, 2015–2025
8.3.1. Cervical Cancer
8.3.2. Anal Cancer
8.3.3. Vaginal Cancer
8.3.4. Penile Cancer
8.3.5. Vulvar Cancer
8.3.6. Oropharyngeal Cancer
8.3.7. Genital Warts
8.3.8. Others
8.4. Global Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
8.5. Global Human Papillomavirus Vaccines Market Forecast, by Indication
8.6. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication
9. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast by Distribution Channel, 2015–2025
9.3.1. Physicians
9.3.2. Wholesalers
9.3.3. Physician Distributors
9.3.4. Government Entities
9.3.5. Public and Private Alliances
9.4. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
9.5. Global Human Papillomavirus Vaccines Market Forecast, by Distribution Channel
9.6. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
10. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Region
10.1. Global Human papillomavirus vaccine Market Snapshot, by Country
10.2. Global Human Papillomavirus Vaccines Market Analysis, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Human Papillomavirus Vaccines Market Forecast, by Region
10.4. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region
11. North America Human Papillomavirus Vaccine Market Analysis
11.1. Policies and Regulations
11.2. Key Findings
11.3. North America Human Papillomavirus Vaccines Market Overview
11.4. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
11.4.1. U.S.
11.4.2. Canada
11.5. Market Attractiveness Analysis
11.6. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
11.6.1. Bivalent
11.6.2. Quadrivalent, and Nonavalent
11.7. Market Attractiveness Analysis
11.8. North America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
11.8.1. Cervical Cancer
11.8.2. Anal Cancer
11.8.3. Vaginal Cancer
11.8.4. Penile Cancer
11.8.5. Vulvar Cancer
11.8.6. Oropharyngeal Cancer
11.8.7. Genital Warts
11.8.8. Others
11.9. Market Attractiveness Analysis
11.10. Market Value Share Analysis by Distribution Channel, 2015–2025
11.10.1. Physicians
11.10.2. Wholesalers
11.10.3. Physician Distributors
11.10.4. Government Entities
11.10.5. Public and Private Alliances
12. Europe Human Papillomavirus Vaccine Market Analysis
12.1. Policies and Regulations
12.2. Key Findings
12.3. Europe Human Papillomavirus Vaccines Market Overview
12.4. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
12.4.1. Germany
12.4.2. France
12.4.3. Italy
12.4.4. Spain
12.4.5. U.K.
12.4.6. Rest of Europe
12.5. Market Attractiveness Analysis
12.6. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
12.6.1. Bivalent
12.6.2. Quadrivalent, and Nonavalent
12.7. Market Attractiveness Analysis
12.8. Europe Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
12.8.1. Cervical Cancer
12.8.2. Anal Cancer
12.8.3. Vaginal Cancer
12.8.4. Penile Cancer
12.8.5. Vulvar Cancer
12.8.6. Oropharyngeal Cancer
12.8.7. Genital Warts
12.8.8. Others
12.9. Market Attractiveness Analysis
12.10. Market Value Share Analysis by Distribution Channel, 2015–2025
12.10.1. Physicians
12.10.2. Wholesalers
12.10.3. Physician Distributors
12.10.4. Government Entities
12.10.5. Public and Private Alliances
13. Asia Pacific Human Papillomavirus Vaccine Market Analysis
13.1. Policies and Regulations
13.2. Key Findings
13.3. Asia Pacific Human Papillomavirus Vaccines Market Overview
13.4. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. Rest of Asia Pacific
13.5. Market Attractiveness Analysis
13.6. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
13.6.1. Bivalent
13.6.2. Quadrivalent, and Nonavalent
13.7. Market Attractiveness Analysis
13.8. Asia Pacific Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
13.8.1. Cervical Cancer
13.8.2. Anal Cancer
13.8.3. Vaginal Cancer
13.8.4. Penile Cancer
13.8.5. Vulvar Cancer
13.8.6. Oropharyngeal Cancer
13.8.7. Genital Warts
13.8.8. Others
13.9. Market Attractiveness Analysis
13.10. Market Value Share Analysis by Distribution Channel, 2015–2025
13.10.1. Physicians
13.10.2. Wholesalers
13.10.3. Physician Distributors
13.10.4. Government Entities
13.10.5. Public and Private Alliances
14. Latin America Human Papillomavirus Vaccine Market Analysis
14.1. Policies and Regulations
14.2. Key Findings
14.3. Latin America Human Papillomavirus Vaccines Market Overview
14.4. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Attractiveness Analysis
14.6. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
14.6.1. Bivalent
14.6.2. Quadrivalent, and Nonavalent
14.7. Market Attractiveness Analysis
14.8. Latin America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
14.8.1. Cervical Cancer
14.8.2. Anal Cancer
14.8.3. Vaginal Cancer
14.8.4. Penile Cancer
14.8.5. Vulvar Cancer
14.8.6. Oropharyngeal Cancer
14.8.7. Genital Warts
14.8.8. Others
14.9. Market Attractiveness Analysis
14.10. Market Value Share Analysis by Distribution Channel, 2015–2025
14.10.1. Physicians
14.10.2. Wholesalers
14.10.3. Physician Distributors
14.10.4. Government Entities
14.10.5. Public and Private Alliances
15. Middle East & Africa Human Papillomavirus Vaccine Market Analysis
15.1. Policies and Regulations
15.2. Key Findings
15.3. Middle East & Africa Human Papillomavirus Vaccines Market Overview
15.4. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
15.4.1. GCC Countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Market Attractiveness Analysis
15.6. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
15.6.1. Bivalent
15.6.2. Quadrivalent, and Nonavalent
15.7. Market Attractiveness Analysis
15.8. Middle East & Africa Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
15.8.1. Cervical Cancer
15.8.2. Anal Cancer
15.8.3. Vaginal Cancer
15.8.4. Penile Cancer
15.8.5. Vulvar Cancer
15.8.6. Oropharyngeal Cancer
15.8.7. Genital Warts
15.8.8. Others
15.9. Market Attractiveness Analysis
15.10. Market Value Share Analysis by Distribution Channel, 2015–2025
15.10.1. Physicians
15.10.2. Wholesalers
15.10.3. Physician Distributors
15.10.4. Government Entities
15.10.5. Public and Private Alliances
16. Competition Landscape
16.1. Human Papillomavirus (HPV) Vaccine Sales Analysis
16.2. Competition Matrix
16.3. Human Papillomavirus (HPV) Vaccine Market Share Analysis, by Company
16.4. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.4.1. Merck & Co., Inc.
16.4.1.1. Company Description
16.4.1.2. Financial Overview
16.4.1.3. Strategic Overview
16.4.1.4. Recent Developments
16.4.1.5. SWOT ANALYSIS
16.4.2. GlaxoSmithKline plc.
16.4.2.1. Company Description
16.4.2.2. Financial Overview
16.4.2.3. Strategic Overview
16.4.2.4. Recent Developments
16.4.2.5. SWOT ANALYSIS
16.4.3. Sanofi
16.4.3.1. Company Description
16.4.3.2. Financial Overview
16.4.3.3. Strategic Overview
16.4.3.4. SWOT ANALYSIS
16.4.4. Johnson & Johnson
16.4.4.1. Company Description
16.4.4.2. Financial Overview
16.4.4.3. Recent Developments
16.4.4.4. SWOT ANALYSIS
16.4.5. AstraZeneca
16.4.5.1. Company Description
16.4.5.2. Financial Overview
16.4.5.3. Recent Developments
16.4.5.4. SWOT ANALYSIS
16.4.6. Serum Institute of India Pvt. Ltd.
16.4.6.1. Company Description
16.4.6.2. Recent Developments
16.4.6.3. SWOT ANALYSIS
16.4.7. Xiamen Innovax Biotech CO., LTD. (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)
16.4.7.1. Company Description
16.4.7.2. SWOT ANALYSIS
16.4.8. General Incorporated Foundation, The Chemo- Sero-Therapeutic Research Institute (Kaketsuken)
16.4.8.1. Company Description
16.4.8.2. Recent Developments
16.4.8.3. SWOT ANALYSIS
16.4.9. Bharat Biotech
16.4.9.1. Company Description
16.4.9.2. SWOT ANALYSIS
List of Tables
Table 01: Opportunity Map, by Valence 2016
Table 02: Opportunity Map, by Indication 2016
Table 03: Opportunity Map, by Distribution Channel 2016
Table 04: Pipeline Analysis
Table 05: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valence, 2015–2025
Table 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 07: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 08: Global Human Papillomavirus Vaccines Market (US$ Mn) Forecast, by Region, 2015–2025
Table 09: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 11: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 12: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 15: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 16: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 19: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 20: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 23: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 24: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 27: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 28: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Human Papillomavirus (HPV) Vaccine Sales Analysis, 2014 – 2016
List of Figures
Figure 01: Global Human Papillomavirus Vaccines Market, by Valence, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Human Papillomavirus Vaccines Market Revenue (%), by Indication, 2016 (A)
Figure 03: By Valence Revenue (%), 2016
Figure 04: By Indication Opportunity Map, 2016
Figure 05: Vaccine Type Opportunity Map, 2016
Figure 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, 2015–2025
Figure 07: Market Value Share, by Valence (2016)
Figure 08: Market Value Share, by Indication (2016)
Figure 09: Market Value Share, by Distribution Channel (2016)
Figure 10: Market Value Share, by Region (2016)
Figure 11: Global Human Papillomavirus Vaccines Market Value Share, by Valence, 2016 and 2025
Figure 12: Global Human Papillomavirus Vaccines Market Attractiveness, by Valence, 2017–2025
Figure 13: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bivalent, 2015–2025
Figure 14: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Quadrivalent, and Nonavalent, 2015–2025
Figure 15: Global Human Papillomavirus Vaccines Vaccines Market Value Share Analysis, by Indication, 2016 and 2025
Figure 16: Global Cervical Cancer Market Revenue, US$ Mn, 2017–2025
Figure 17: Global Anal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 18: Global Vaginal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 19: Global Penile Cancer Market Revenue, US$ Mn, 2017–2025
Figure 20: Global Vulvar Cancers Market Revenue, US$ Mn, 2017–2025
Figure 21: Global Oropharyngeal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 22: Global Genital Warts Market Revenue, US$ Mn, 2017–2025
Figure 23: Global Others Market Revenue, US$ Mn, 2017–2025
Figure 24: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication
Figure 25: Global Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 26: Global Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 27: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Wholesalers Vaccines, 2015–2025
Figure 28: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physicians Vaccines, 2015–2025
Figure 29: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Government Entities Vaccine, 2015–2025
Figure 30: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physician Distributors Vaccine, 2015–2025
Figure 31: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Vaccines, 2015–2025
Figure 32: Global Human Papillomavirus Vaccines Market Analysis by Region, 2016 and 2025
Figure 33: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region
Figure 34: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 35: North America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 36: North America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 37: North America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 38: North America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 39 highlights market value share of the HPV vaccines market in Europe, by indication, for 2016 and 2025.
Figure 39: North America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 40: North America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 41: North America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 42: North America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 43: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 44: Europe Human Papillomavirus Vaccines Market Value Share, by Country, 2016 and 2025
Figure 45: Europe Human Papillomavirus Vaccines Market Attractiveness, by Country, 2017–2025
Figure 46: Europe Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 47: Europe Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 48: Europe Human Papillomavirus Vaccines Market Value Share, by Indication, 2015 and 2025
Figure 49: Europe Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 50: Europe Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 51: Europe Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 52: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 53: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 54: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 55: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 56: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 57: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 58: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 59: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 60: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 61: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 62: Latin America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 63: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 64: Latin America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 65: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 66: Latin America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 67: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 68: Latin America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 69: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 70: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 71: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 72: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 73: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 74: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 75: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 76: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 77: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 78: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 79: Human Papillomavirus (HPV) Vaccine Market Share, by Company, 2016
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
